Lexaria Bioscience Corp. (NASDAQ: LEXX) Affirms Product Superiority in Its 2023 Human Oral Nicotine Study, NIC-H22-1

• Lexaria’s NIC-H22-1 study proved that its patented DehydraTECH(TM)-nicotine tobacco-free pouch was statistically significantly faster-acting than alternatives
• The study, which involved 36 participants, embraced a randomized, double-blind, cross-over study design
• It also affirmed Lexaria’s product superiority while also showing DehydraTECH’s potential

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released results from its 2023 human oral nicotine study NIC-H22-1. Of note was its patented DehydraTECH(TM)–nicotine tobacco-free pouch product superiority, particularly when pitted against world-leading brands ZYN(R) and on!(R). The study proved that Lexaria’s product was statistically significantly faster than the two alternatives in the median time required to reach comparable maximum nicotine concentrations (“Tmax”) levels (https://cnw.fm/17JMQ).

Lexaria’s CEO, Chris Bunka, lauded his team for this achievement, especially considering they had to work without as many resources as global multi-billion-dollar behemoths. He also lauded the company’s technology, citing its potential and advantages, as demonstrated in the study.

“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” he noted (https://cnw.fm/17JMQ).

Several intriguing data trends were observed from the study. For one, most of the subjects reported that they felt euphoric at all time points when they used Lexaria’s product. Lexaria also got the highest endorsement score, with statistical significance demonstrated at the second dosing visit. The highest percentage of users reporting that they considered the experience “pleasurable” at the 30-minute mark were also Lexaria users, and the company also scored best on the enjoyment scale.

Negative effects, meanwhile, such as nausea and severe hiccups were experienced more by the mass-market products than by the Lexaria formulation.

The study embraced a randomized, double-blind, cross-over study design involving 36 participants, all long-time heavy cigarette smokers who smoke at least ten cigarettes a day. Subjective effects, both positive and adverse, were assessed at baseline, 5 minutes, 30 minutes, and 120 minutes using a questionnaire to capture 25 different effects. All laboratory procedures for the study were conducted entirely by U.S.—based, third-party independent contract service providers (https://cnw.fm/17JMQ).

The results from this study not only validate Lexaria’s efforts but also affirm its product superiority while also showing DehydraTECH’s potential. This is a tremendous achievement for the company, given that this has been achieved in just five years. It reflects the company’s commitment to making the world a better place and its resolve to create value for its shareholders.

“We’ve always had an overwhelming determination and fierce conviction that we can make the world a better place and reduce the carnage caused by smoked cigarettes, and now we have human study data that demonstrates the advantages of DehydraTECH processed nicotine relative to the competitive landscape,” noted Mr. Bunka (https://cnw.fm/17JMQ).

For company information, visit the company’s website at www.LexariaBioscience.com 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About HempWire

HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.buti

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website try  applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/Disclaimer

Do you have a questions or are you interested in working with HW? Ask our Editor

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net

HempWire is part of the InvestorBrandNetwork.